Please login to the form below

Not currently logged in
Email:
Password:

mepolizumab

This page shows the latest mepolizumab news and features for those working in and with pharma, biotech and healthcare.

Dupixent helps put Sanofi back on growth track

Dupixent helps put Sanofi back on growth track

They think the asthma indication could be worth $2.5bn on its own, although it’s a crowded market with GlaxoSmithKline’s Nucala (mepolizumab), Teva’s Cinqair (reslizumab) and AstraZeneca’s

Latest news

More from news
Approximately 9 fully matching, plus 44 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Publicis Resolute

Publicis Resolute provides real-life practical solutions to your issues, without fuss or fluff. We are an experienced team with a...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics